Leading pharmaceutical and biotech product development consultancy Boyds has enhanced its clinical and medical affairs services offering following the acquisition of Blue Duck Consulting.
Since 2013, Blue Duck has provided expert preclinical and clinical drug development strategies and specialist monitoring and project management of clinical operations services in a range of therapeutic areas, led by its founder Dr Karen O’Hanlon, who joins Boyds as Director of Clinical Operations.
An experienced programme manager with 17 years’ experience in preclinical, clinical and analytical drug…
Cambridge, UK, 05 September, 2019: Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the introduction of a new ReCIVA® Breath Sampler and CASPERTM Portable Air Supply, designed to support internal biomarker discovery programs and those of academic and biopharma clients, and to measure levels of known volatile organic compounds (VOCs) on breath.
The discovery of biomarkers, whether in blood, tissue, or breath, can be difficult. Issues can arise throughout the process, with two of the most challenging being…
Leiden, 03 September 2019: Today, Batavia Biosciences announced that the company has signed a license agreement to utilize Horizon Discovery’s GS knockout CHO K1 cell line expression system for the development of high yield antibody-expressing cell lines. Initially, Batavia will deploy the system for production of a potent Zika virus neutralizing antibody, working in collaboration with Vanderbilt University Medical Center (VUMC) and IDBiologics, a company which focuses on developing human antibodies for the prevention, treatment and cure of infectious diseases.
The Zika virus…
AMSBIO reports on a paper** from the Malmberg Lab at Oslo University Hospital and the Norwegian Radium Hospital Institute for Cancer Research (Norway) that suggests a mechanism by which Natural Killer (NK) cell education operates through modulation of the lysosomal compartment under the influence of inhibitory receptor–ligand interactions.The research reveals that educated NK cells expressing self-MHC specific inhibitory killer cell immunoglobulin-like receptors (KIR) accumulate granzyme B and Chondroitin Sulfate-4 in dense-core secretory…
AMSBIO offers a comprehensive range of high quality Heparan Sulfate (HS) antibodies from F69-3G10, F58-10E4 and JM403 clones, which have been proven ideal for targeted binding of HS in Heparan Sulfate Proteoglycans (HSPG) research.Heparan Sulfate is synthesized as the glycosaminoglycan (GAG) component of Heparan Sulfate Proteoglycans. It is expressed on the cell surface of virtually all cell types and basement membranes in mammals. It displays specific interactions with many biologically active proteins and, thus, is involved in many important biological processes.Many researchers…
Cambridge, UK, 27 August 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced an updated version of its Cyto-Mine® Studio Software Suite, a collection of software controlling operation of its Cyto-Mine Single Cell Analysis System, data acquisition and follow-up analysis. The latest software version includes new functionality to further enhance users’ workflows in biologics discovery and cell line development.Sphere Fluidics’ Cyto-Mine integrates selective screening of tens of millions of single cells…
20th August 2019: Marks & Clerk, the UK’s largest Patent and Trade Mark Attorney firm, has boosted its team in Cambridge with the promotion of two new Partners. Steven Gurney, a specialist in the pharmaceutical sector and Matthew Pinney who specialises in software and telecommunications, both join the Marks & Clerk partnership.
The firm, which alongside its office in Cambridge has bases across the UK as well as in the EU, North America and Asia, is one of Europe’s largest teams of intellectual property specialists.
Alongside promoting new Partners, the team in Cambridge has also been…
Cambridge, UK, 21 August 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has opened a new office space at Granta Park in Cambridgeshire, UK. The new facilities support the Company’s accelerated expansion and accommodate its plans for further growth.
Sphere Fluidics recently closed a $4.8 million USD (£3.7 million) funding round, enabling it to hire 10 new staff to expand commercial capabilities and facilitate service and support for its Cyto-Mine® Single Cell Analysis System. Sphere…
Cambridge, UK, 20 August: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to welcome Tim Rea, an investor at BGF, to its board.
Tim has been active in the venture capital and start-up ecosystem for over 20 years across a broad range of sectors, stages and geographies. He is particularly passionate about the application of new, disruptive technologies into the healthcare and life sciences ecosystems.
An investor at BGF, the UK and Ireland’s most active investor in growing businesses…